InViragen (Ft. Collins) is committed to developing life-saving vaccines to protect against emerging infectious diseases worldwide and continues on a very positive trajectory. Building upon last years $2.7M NIH Dengue vax grant InViragen has now confirmed financial support from the Pediatric Dengue Vaccine Initiative. This non-dilutive financing will enable the manufacture of the Dengue vax, in collaboration with Shantha Biotechnics, for use in human clinical trials. Dengue fever is a mosquito-borne illness, prevalent in tropical and subtropical countries throughout the world, approximately 3.5 billion people live in the endemic region and roughly 100 million people are infected with Dengue each year, according to recent published estimates. In addition, a $600,000 NIH grant was recently awarded for the construction and testing of a novel vax against the H5N1 Avain Influenza virus. Dan Stinchcomb, President & CEO of InViragen continues to orchestrate a robust product pipeline that in addition to the Dengue and Avain Influenza vaccines also includes advancing pre-clinical studies of West Nile, Plague and Smallpox vaccines.
If you enjoyed this post get free email updates (here).